

REMARKS

Firstly, Applicants would like to thank the Examiner for allowing claims 58, 59, and 65-67. Claims 11-13 and 53-57 have been cancelled, and claims 60 and 68 have been amended. Claims 58-60 and 65-68 remain pending in the application. No new matter has been added.

Objections to the Specification

Claim 11 is objected to because of a slight informality. Applicants have cancelled said claim, thereby obviating the objection.

Rejection Under 35 USC §112, ¶ 1

The Examiner rejects claims 53-57, 60-64, and 68-72 under 35 USC §112, ¶ 1, because the specification, "while enabling for an isolate antibody that specifically recognizes amino acid residues 791-1054 or tenascin W for the manufacture of a medicament for the treatment of *breast cancer*, does not reasonably provide enablement for an isolate antibody that specifically recognizes tenascin W for the prophylaxis of *just any cancer* or the treatment of *just any cancer* or a disease or condition *characterized by excessive bone growth*" (emphasis added by Applicants).

While in no way acquiescing to the Examiner's rejections, Applicants have cancelled claims 54-57, 61-64, and 69-72, thereby obviating the rejection with respect to those claims. Applicants have also amended claims 53, 60, and 68 to incorporate the breast cancer-specific limitations of some of the previously presented dependent claims therefrom (now cancelled). In this way, Applicants now present claims 53, 60, and 68 in a breast cancer-specific fashion that meets the Examiner's enablement requirements. Applicants reserve the right to pursue the subject matter contained therein in future applications.

Rejection Under 35 USC §102

The Examiner rejects claims 11-13 and 53-57 under 35 USC §102(e), as being anticipated by Ni, et al. (US Patent Publication 2002/0151009)(hereinafter, "Ni reference"). While in no way acquiescing to the Examiner's rejections, Applicants have cancelled claims 54-57, 61-64, and 69-72, thereby obviating the rejection with respect to those claims. Applicants reserve the right to pursue the subject matter contained therein in future applications.

Applicants respectfully request entry of the amendments to the claims and the specification and submit no new matter is added thereby. Should the Examiner have any questions, please contact the undersigned attorney.

This response is made with three months' extension. However, if it is deemed that additional fees are required, the Commissioner is authorized to charge Deposit Account No. 50-4409 in the name of Novartis for any fees due.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(617) 871-3343

/Paul J. Paglierani/
Paul J. Paglierani
Attorney for Applicants
Reg. No. 52,498

Date: March 10, 2008